BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.

@article{Biedenbach1998BAY1A,
  title={BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.},
  author={Douglas J. Biedenbach and Mary S. Barrett and Matthew A.T. Croco and Ronald N. Jones},
  journal={Diagnostic microbiology and infectious disease},
  year={1998},
  volume={32 1},
  pages={
          45-50
        }
}
BAY 12-8039 or moxifloxacin is a new 8-methoxyquinolone with documented, improved activity against Gram-positive cocci and anaerobic bacteria. This study tested 1250 commonly isolated respiratory tract pathogens (251 Moraxella catarrhalis, 499 Haemophilus influenzae, 500 Streptococcus pneumoniae) from 1996-1997 clinical infections at more than 30 medical centers. Among the M. catarrhalis strains (81% beta-lactamase-positive) the BAY 12-8039 MIC90 was 0.06 microgram/mL, a potency equal to… CONTINUE READING
BETA

Similar Papers

Loading similar papers…